
|Videos|July 21, 2017
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Advertisement
- 67-year-old female, former smoker (30 pack-years, quit 10 years ago) presented to her pulmonologist with increased cough, dyspnea and hemoptysis.
- Past medical history of mild COPD.
- Patient swims three times a week and is continuing normal activities.
- ECOG PS was assessed as 1.
- CT scan of chest and abdomen show a lower right lobe lung nodule with several small liver lesions.
- PET/CT scan indicated lung cancer with liver metastases.
- Core needle biopsy was performed in the liver. Pathology report showed adenocarcinoma consistent with non-small cell lung cancer (NSCLC).
- Mutation testing showed aBRAF V600Emutation.
- PD-L1 status was negative.
- Patient was started on pemetrexed and carboplatin.
- After 3 of 6 planned cycles patient showed worsening signs of dyspnea with a weight loss of 10%.
- Repeat CT scan showed progression of primary lesion.
- Patient was started on dabrafenib + trametinib.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































